Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR), to no one’s surprise, remains volatile. Notably, the stock hit an intraday low of $17.60 on October 5th, and closed Thursday 19.5% … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) announced prescription trend data this morning for its primary revenue driver, H.P. Acthar Gel (Acthar), and the news is positive, sending the … Continue Reading
Read nowLong Ideas - Breaking news that health insurer, Oxford Health, will cover HP Acthar Gel (Acthar), looks like a major win for Questcor Pharmaceuticals (NASDAQ:QCOR), and the stock … Continue Reading
Read nowLong Ideas - By now, the bear story on Questcor Pharmaceuticals (NASDAQ:QCOR) is well understood, with health insurer Aetna (NYSE:AET) indicating that it will make it next-to-impossible to … Continue Reading
Read nowRecap - Shares of HEB furtively peaked on Monday following an announcement that Ampligen’s advisory committee meeting date had been set, but shares were unsuccessful in maintaining … Continue Reading
Read nowMost Popular - Questcor Pharmaceuticals (NASDAQ:QCOR) shares are taking another pounding Monday after the company announced in an 8-k that it “became aware of a U.S. government investigation … Continue Reading
Read nowRecap - Questcor Pharmaceuticals imploded. We said shares would rebound after tuning into the company’s conference call and coming out thinking Questcor’s lead product, H.P. Acthar Gel, … Continue Reading
Read now